The development of a new therapeutic system for the obesity: Transnasal delivery of the peptide drug to the brain
| Project/Area Number |
16K08208
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Kobe Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Takayama Kentaro
Tanaka Akiko
Kimura Shunsuke
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 肥満症 / 鼻腔内投与 / 生理活性ペプチド / 脳 / Neuromedin U / ペプチド / 脳内送達 / 肥満 / 薬学 / 薬物送達 |
|---|
| Outline of Final Research Achievements |
The development of the new therapeutic system for the obesity was attempted, using new drug candidate (CPN), which exhibits the safe antiobesity potency. CPN was applied to the nasal cavity for the improvement of the brain delivery of CPN, because CPN acts on the brain. After nasal application, the brain concentration of CPN is higher in spite of the lower plasma concentration, as compared to intravenous injection. The antiobesity effect of CPN was examined by the body weight change of the animals. No inhibition of body weight gain was observed after intravenous injection. On the other hand, after nasal application of the same dose, significant inhibition of the body weight gain was observed. The findings suggest the possibility of the development of the new therapy for the obesity by nasal application of CPN.
|
| Academic Significance and Societal Importance of the Research Achievements |
従来、肥満症の治療に用いられてきた医薬品は対症療法の域を出ず、有効性、安全性ともに問題があったが、CPNは安全性に優れ、鼻腔内投与することで、有効性を担保することができた。また、CPN以外にも脳疾患に優れた効果を示すペプチドが存在するが、治療に応用するためには、脳への送達が課題である。本研究で検討を行った鼻腔内投与は他のペプチドの脳内送達にも有用であり、社会問題となりつつある認知症に対する画期的な治療法開発の可能性を秘めている。
|
Report
(4 results)
Research Products
(12 results)
-
-
-
-
[Presentation] 鼻腔内投与によるCPN-116の脳内送達2017
Author(s)
坂根稔康, 湯谷玲子,寺岡麗子, 前田千晶, 田中晶子, 武田康嗣, 高山健太郎, 井上大輔, 古林呂之, 草森浩輔, 勝見英正, 林 良雄, 山本 昌
Organizer
日本薬学会第137年会
Place of Presentation
仙台国際センター(仙台市）
Year and Date
2017-03-25
Related Report
-
[Presentation] Transnasal delivery of the peptide to the brain2017
Author(s)
Toshiyasu Sakane, Reiko Yutani, Reiko Teraoka, Akiko Tanaka, Yuki Takemura, Koji Taketa, Kentaro Takayama, Yoshio Hayashi, Kosuke Kusamori, Hidemasa Katsumi, Akira Yamamoto
Organizer
International Symposium on Drug Delivery and Pharmaceutical Sciences
Place of Presentation
京都リサーチパーク バズホール(京都市)
Year and Date
2017-03-09
Related Report
Int'l Joint Research
-
-
-
-
-
[Presentation] Transnasal delivery of peptide agonist specific to neuromedin U receptor 2 to the brain for the treatment of obesity2016
Author(s)
Akiko Tanaka, Yuki Takemura, Daisuke Inoue, Tomoyuki Furubayashi, Koji Taketa, Kentaro Takayama, Yoshio Hayashi, Kosuke Kusamori, Hidemasa Katsumi, Toshiyasu Sakane, Akira Yamamoto
Organizer
2016 Controlled Release Society Annual Meeting and Exposition
Place of Presentation
Washington State Convention Center （Seattle, USA）
Year and Date
2016-07-17
Related Report
Int'l Joint Research
-
-
